COMP <GO>
MTNB vs OGEN // GROSS PROFIT MARGIN
Matinas Biopharma Holdings Inc. (NYSE) VS. Oragenics Inc. (NYSE) • 15-METRIC TALLY: MTNB 3
— OGEN 0
■ METRIC PARITY
LAST: $1.51 (-20.53%) • MKT CAP: $1.9M
gross-margins
—
LAST: $0.37 (-0.05%) • MKT CAP: $1.7M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MTNB VS. OGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MTNB | OGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | MTNB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.7 | 28.1 | +15.59 | MTNB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.9M | $1.7M | $172.7K | MTNB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MTNB REV | OGEN REV | MTNB GROSS % | OGEN GROSS % | MTNB FCF | OGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$7.0M | -$9.2M |
| FY 2024 | $0 | $0 | — | — | -$15.9M | -$8.6M |
| FY 2023 | $1.1M | $37.7K | — | — | -$15.3M | -$7.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MTNB // BETA —
OGEN // BETA —